This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
by Zacks Equity Research
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
GSKNegative Net Change RGENPositive Net Change ANIKNegative Net Change ANABNegative Net Change
biotechs
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
by Zacks Equity Research
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
ACADNegative Net Change RGENPositive Net Change ACIUPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
by Ahan Chakraborty
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
HALO Stock Rises 36% in a Month: Here's What You Should Know
by Zacks Equity Research
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
HALONegative Net Change JNJNegative Net Change RGENPositive Net Change ARGXPositive Net Change
biotechs
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
by Ekta Bagri
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
by Sundeep Ganoria
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
NBIXNegative Net Change TEVANegative Net Change ACADNegative Net Change
biotechs medical
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
by Sundeep Ganoria
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
NBIXNegative Net Change BMYNegative Net Change TEVANegative Net Change
biotechs medical
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
by Sundeep Ganoria
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
NBIXNegative Net Change BMYNegative Net Change TEVANegative Net Change
biotechs medical
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
by Zacks Equity Research
Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.
MRKNegative Net Change MRNANegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechs pharmaceuticals